Figure 2From: Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trialTrough FEV 1 on Day 1 and at Weeks 12 and 26. Data are least squares means ± standard error; *p < 0.001; Treatment differences: Day 1 = 105 ± 10.9 mL; Week 12 = 108 ± 14.8 mL; Week 26 = 113 ± 16.5 mL.Back to article page